Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Sales of Investments
Cash received from selling or redeeming investments.
Verastem, Inc.NASDAQ: VSTM
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments turns negative
Q1 FY2026 sales of investments was -$119K, compared with $0 a year earlier. Trailing-twelve-month sales of investments was -$119K. Over 3 fiscal years it compounded at -93.0% a year.
Context
- Sales of investments amounted to 0.1% of revenue in FY2025, down 599.9 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near -$119K or moves back toward the trailing-twelve-month quarterly average of -$29.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 29K USD
- Year-over-year change
- -100.0%
- 4-year CAGR
- -86.5%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29K | -100.0% |
| FY2024 | 2024-12-31 | 60M | +15.4% |
| FY2023 | 2023-12-31 | 52M | -38.1% |
| FY2022 | 2022-12-31 | 84M | -3.1% |
| FY2021 | 2021-12-31 | 86.73M | — |
Sales of Investments vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 sales of investments of $119K is the 10th largest of the 11 companies compared; the peer median is $115.6M.
- Its year-over-year change of -100.4% is the 9th highest of 10, against a peer median of -14.3%.
- Sales of investments amounts to 0.2% of revenue for VSTM, versus a peer median of 590.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $227.98M | +3713.6% | — | — |
| LTM Mar 2026 | $225M | -27.4% | +24.5% | — | |
| LTM Mar 2026 | $221.34M | -5.3% | -8.2% | 634.9% | |
| LTM Mar 2026 | $212M | -16.7% | +13.5% | 751.1% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $140M | -11.6% | +141.1% | — |
| LTM Jun 2026 | $139.19M | -130.9% | -7.5% | 81.9% | |
| LTM Mar 2026 | $91.2M | -48.9% | -8.9% | 545.4% | |
| LTM Mar 2026 | $67.84M | +28.1% | -17.5% | 12922.7% | |
| LTM Mar 2026 | $9M | -14.3% | — | — | |
| LTM Mar 2026 | $119K | -100.4% | -93.0% | 0.2% | |
| LTM Jun 2024 | $0 | — | -61.4% | 0.0% | |
| Peer median (excluding VSTM) | $115.6M | -14.3% | -7.9% | 590.2% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Depreciation & Amortization | 72K | (36K) | 62K | 26K | 728K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.71M | 6.05M | 5.86M | 7.34M | 9.4M |
| Change in Working Capital | 584K | 3.9M | (957K) | 3.72M | 26M |
| Accounts Receivables | (277K) | 485K | 31K | (200K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 0 | (1.83M) |
| Accounts Payables | 623K | 2.6M | 2.28M | (3.16M) | 8.42M |
| Other Working Capital | 238K | 816K | (3.27M) | 7.08M | 28.23M |
| Other Non-Cash Items | 9.33M | 228K | (4.06M) | 14.78M | 35.83M |
| Operating Cash Flow | (53.5M) | (63.67M) | (86.46M) | (104.77M) | (137.51M) |
| Capital Expenditures | (196K) | 0 | 0 | (28K) | 0 |
| Acquisitions (Net) | 9.33M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (86.44M) | (17.82M) | (96.45M) | 0 | 0 |
| Sales of Investments | 86.73M | 84M | 52M | 60M | 29K |
| Other Investing Activities | (9.33M) | 0 | 0 | 5K | (29K) |
| Investing Cash Flow | 87K | 66.19M | (44.45M) | 59.97M | (9.62M) |
| Debt Repayment | 0 | 24.15M | 14.62M | (150K) | 32.42M |
| Common Stock Issued | 6.72M | 27.35M | 91.42M | 14.22M | 230.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 162K | 282K | 57K | 40.71M | 0 |
| Financing Cash Flow | 6.89M | 51.78M | 134.19M | 54.78M | 263.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.53M) | 54.3M | 3.29M | 9.98M | 116.17M |
| Free Cash Flow | (53.7M) | (63.67M) | (86.46M) | (104.8M) | (137.51M) |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.